Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis

ABSTRACT Background Rademikibart, a potent, next‐generation, optimized IL‐4Rα‐targeting antibody, achieved its primary and secondary endpoints as a treatment for adults with moderate‐to‐severe atopic dermatitis (AD) in the CBP‐201‐WW001 Phase 2, randomized, double‐blind, placebo‐controlled trial (NC...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jonathan I. Silverberg, Emma Guttman‐Yassky, Raúl Collazo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2026-06-01
coleção:	JEADV Clinical Practice
Assuntos:	atopic dermatitis dosing frequency efficacy quality of life rademikibart sleep
Acesso em linha:	https://doi.org/10.1002/jvc2.70200
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!